Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aventis--World's No. 1 Drugmaker -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (5)	3/2/2000 10:21:00 AM
From: Mike McFarland	Read Replies (1) \| Respond to of 22

Allegra once-daily dosage approved biz.yahoo.com Aventis will be muscling into Schering-Plough Corp.'s allergy territory. Schering-Plough's best selling drug is Claritin, another daily dose medication, but analysts don't think it will substantially hurt Claritin's sales. P&G, Aventis say 12 European nations approve Actonel biz.yahoo.com Actonel received marketing approval in Brazil in January. In the United States, Actonel is currently under regulatory review by the Food and Drug Administration, the companies said.